Sana Biotechnology

### Executive Summary Sana Biotechnology raised $636.2M in a Regulation D private placement, with first sale on 2025-10-12. The filing lists Andreessen Horowitz and Sands Capital as related persons, signaling strong institutional backing for its synthetic biology and intracellular mRNA delivery platform. ### Investor Edge Watch for subsequent D/A amendments that could reveal additional investors or changes in terms, and monitor Sana's pipeline for any public announcements of IND filings or partnership deals within 6-12 months. ### Sector capital positioning This $636.2M raise is one of the largest private capital inflows in synthetic biology and mRNA delivery, indicating sustained investor appetite for next-generation therapeutic platforms. ### Convergence Signals No direct public signals (patents, contracts, legislation) are evident from the filing data alone. However, the involvement of top-tier VCs suggests potential upcoming clinical milestones or partnerships. ### Key Takeaways - Sana Biotechnology raised $636.2M in private capital, a very large round for synthetic biology. - Andreessen Horowitz and Sands Capital are listed as related persons, indicating high-profile backing. - First sale date is 2025-10-12, which is in the future; this may be a data anomaly or pre-arranged placement. ### Risk Indicators & Flags The first sale date (2025-10-12) is after today's date (2026-06-02), which is inconsistent and could indicate a filing error or a forward-looking notice. No D/A amendments are present yet, but the unusual date warrants verification. ### Verification & References Filing is a Form D (initial notice) with SEC accession 0001702600-24-20263. Verify at https://www.sec.gov/cgi-bin/browse-edgar?company=Sana%20Biotechnology&type=D&action=getcompany. First sale date 2025-10-12 is in the future relative to today's date (2026-06-02), which is unusual and may indicate a data entry error or forward-looking filing.